Table 1.
LV morphology and in vivo cardiac performance measured by echocardiography
| WT | TnIPKA− | MyBPCPKA− | DBLPKA− | |
|---|---|---|---|---|
| BW (g) | 28.04 ± 0.65 | 27.50 ± 0.94 | 26.47 ± 1.43 | 25.40 ± 2.15 |
| LV mass/BW | 3.67 ± 0.11 | 3.80 ± 0.19 | 5.60 ± 0.39† | 5.11 ± 0.21† |
| PWd (mm) | 0.85 ± 0.02 | 0.88 ± 0.01 | 1.05 ± 0.05† | 0.98 ± 0.04† |
| PWs (mm) | 1.19 ± 0.03 | 1.25 ± 0.02 | 1.35 ± 0.05† | 1.29 ± 0.03 |
| EDV (μL) | 50.6 ± 2.3 | 55.6 ± 2.7 | 74.4 ± 4.7† | 70.7 ± 3.3† |
| ESV (μL) | 11.1 ± 1.1 | 12.3 ± 1.6 | 29.8 ± 3.3† | 27.2 ± 2.2† |
| IVRT (ms) | 19.44 ± 1.14 | 18.78 ± 1.42 | 27.31 ± 1.43† | 28.80 ± 1.02† |
| HR (beats min–1) | 416 ± 11 | 434 ± 12 | 439 ± 10 | 415 ± 10 |
| HR (beats/min) + dobutamine | 496 ± 9* | 514 ± 9* | 502 ± 6* | 489 ± 7* |
| FS (%) | 37.14 ± 1.31 | 37.50 ± 1.34 | 30.12 ± 1.73† | 29.17 ± 1.69† |
| FS (%) + dobutamine | 58.90 ± 2.04* | 54.23 ± 2.23* | 36.90 ± 1.45*, † | 34.46 ± 2.03*, † |
| EF (%) | 74.15 ± 1.54 | 73.51 ± 1.76 | 64.84 ± 2.68† | 62.39 ± 2.35† |
| EF (%) + dobutamine | 93.00 ± 0.99* | 88.81 ± 1.62* | 74.16 ± 1.77*, † | 70.71 ± 2.65*, † |
LV mass/BW, ratio of LV and body weight; PWd, posterior wall thickness in diastole; PWs, posterior wall thickness in systole; EDV, end diastolic volume; ESV, end systolic volume. Values are expressed as the mean ± SEM from eight mice per group. *Significantly different from the corresponding baseline group (without dobutamine treatment) (P < 0.05). †Significantly different from WT (P < 0.05).